Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial

BACKGROUND: The US Food and Drug Administration approved sacubitril/valsartan for patients with chronic heart failure (HF) with reduced ejection fraction in 2015 on the basis of the results of the PARADIGM‐HF (Prospective Comparison of ARNI [Angiotensin Receptor Neprilysin Inhibitor] With ACEI [Angi...

Descripción completa

Detalles Bibliográficos
Autores principales: DeVore, Adam D., Mi, Xiaojuan, Thomas, Laine, Sharma, Puza P., Albert, Nancy M., Butler, Javed, Hernandez, Adrian F., Patterson, J. Herbert, Spertus, John A., Williams, Fredonia B., Duffy, Carol I., McCague, Kevin, Fonarow, Gregg C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220559/
https://www.ncbi.nlm.nih.gov/pubmed/29895587
http://dx.doi.org/10.1161/JAHA.118.009237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220559/
https://www.ncbi.nlm.nih.gov/pubmed/29895587
http://dx.doi.org/10.1161/JAHA.118.009237

Ejemplares similares